Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2123 • ACR Convergence 2023
Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?
Jia-Feng Chen¹, Tien-Tsai Cheng² and Hong-Yo Kang³, ¹Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, ²Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan, ³Graduate Institute of Clinical Medical Sciences, Chang Gung University, College of Medicine, Kaohsiung, Taiwan
Background/Purpose: Trabecular bone score (TBS) of lumbar spine is a dual X-ray densitometry (DXA)-based tool to evaluate bone microarchitecture, providing information on bone quality in…
Abstract Number: 2139 • ACR Convergence 2023
Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort
Namrata Singh¹, Aaron Baraff², K Wysham³, Punyasha Roul⁴, Grant Cannon⁵, Brian Sauer⁶, Geoffrey Thiele⁴, Bryant England⁴, Ted R Mikuls⁷ and Joshua Baker⁸, ¹University of Washington, Bellevue, WA, ²VA Puget Sound Seattle, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: A prior study suggested a higher risk of cancer mortality in patients with rheumatoid arthritis (RA) with higher levels of circulating leptin, an adipocytokine…
Abstract Number: 2155 • ACR Convergence 2023
The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies
Peter C. Taylor¹, Arthur Kavanaugh², Peter Nash³, Janet Pope⁴, Georg Pongratz⁵, Bruno Fautrel⁶, Rieke Alten⁷, Ken Hasegawa⁸, Shangbang Rao⁹, Dick de Vries¹⁰, Pieter-Jan Stiers¹¹, Chris Watson¹² and René Westhovens¹³, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴University of Western Ontario, London, ON, Canada, ⁵Faculty of Medicine, Regensburg University, Regensburg, Germany, Regensburg, Germany, ⁶Sorbonne Université APHP, Paris, France, ⁷Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ⁸Global Medical Affairs Research, Gilead Sciences, Inc., Foster City, CA, ⁹Biostatistics, Gilead Sciences, Inc., Foster City, CA, ¹⁰Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, ¹¹Biostatistics, Galapagos NV, Mechelen, Belgium, ¹²Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ¹³Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post hoc analysis…
Abstract Number: 2172 • ACR Convergence 2023
Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients
Ana Serrano-Combarro¹, Belén Atienza-Mateo², libe Ibarrola-Paino³, Ivette Casafont-Sole⁴, Rafael Benito Melero-Gonzalez⁵, Alba Perez Linaza⁶, Santos Castañeda⁷, Rafaela Ortega Castro⁸, Natalia Mena Vazquez⁹, Nuria Vegas Revenga¹⁰, Lucia Cristina Dominguez Casas¹¹, Elena Cañadillas-Sanchez¹², Miriam Retuerto-Guerrero¹³, Lorena Perez-Albadalejo¹⁴, Ruben Lopez-Sanchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez-Viejo¹⁸, Gema Bonilla¹⁹, Olga Maiz-Alonso²⁰, Carmen carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno²³, Ana Urruticoechea²⁴, Sergio Ordonez-Palau²⁵, Carmen Gonzalez-Montagut Gomez²⁶, andrea Garcia-Valle²⁷, Marta López²⁸, Fernando Lozano²⁹, Tomás Vazquez-Rodriguez³⁰, Maria Martin-Lopez³¹, Juan Maria Blanco-Madrigal³², Cristina Arciniega³³, Ignacio Brana Abascal³⁴, Jesus Loarce-Martos³⁵, Emilio Giner-Serret³⁶, Virginia Ruiz-Esquide³⁷, Clara ventin-Rodriguez³⁸, Marina Rodriguez-lopez³⁹, Pablo Andujar-Brazal⁴⁰, Julia Fernandez-Melon⁴¹, Lilian Maria Lopez⁴², Antonio Juan Mas⁴³, carlos Fernandez-Diaz⁴⁴, Javier Loricera⁴⁵, Diego Ferrer⁴⁶ and Ricardo Blanco⁴⁷, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶SERV. REUMATOLOGIA, Cadiz, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Spain, ⁹IBIMA, Málaga, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universtario San Agustin, Oviedo, Spain, ¹²Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Rheumatology, Hospital Universitario de León, León, Spain, ¹⁴Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ¹⁹Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Can Misses, Ibiza, Spain, ²⁵H. Arnau de Vilanova, Lleida, Spain, ²⁶H. Clínico Universitario de Valladolid, Valladolid, Spain, ²⁷Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁸Hospital Universitario Arava, Pamplona, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁰Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³¹Hospital 12 de Octubre, Madrid, Spain, ³²Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ³³Hospital de Mérida, Mérida, Spain, ³⁴Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁵Ramón y Cajal University Hospital, Madrid, Spain, ³⁶Hospital Royo Villanova, Teruel, Spain, ³⁷Hospital Clinic, Rheumatology, Barcelona, Spain, ³⁸Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, ³⁹Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ⁴⁰Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴¹Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴²Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴³Son Llazter University Hospital, Palma, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, ⁴⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁶Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD. Clinical trials have shown…
Abstract Number: 2452 • ACR Convergence 2023
Assessment of Association Between Hydroxychloroquine Use and Toxic Retinopathy, Overall and by Indication, in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Rachel Robbins¹, Toni Rush² and Jess Edison³, ¹Walter Reed National Military Medical Center, Germantown, MD, ²Health Research Tx, Pace, FL, ³Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD
Background/Purpose: While generally believed to be a safe, well-established treatment, hydroxychloroquine (HCQ) use is associated with irreversible retinal toxicity requiring regular monitoring. The objective of…
Abstract Number: 2542 • ACR Convergence 2023
Impact of Concomitant Methotrexate on Disease Activity After Tapering Abatacept in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jun Won Park¹, Min Jung Kim², Hyoun-Ah Kim³, Jin Hyun Kim⁴ and Kichul Shin⁵, ¹Seoul National University Hospital, Seoul, South Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ³Ajou University School of Medicine, Suwon, South Korea, ⁴Chungnam National University College of Medicine, Daejeon, South Korea, ⁵Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea
Background/Purpose: Recent randomized-controlled studies have suggested that tapering bDMARDs and/or csDMARDs after achieving sustained remission in patients with rheumatoid arthritis (RA) can be considered. However,…
Abstract Number: 0041 • ACR Convergence 2023
Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment
Jia Li, Yanrong Cai, Xin Guan, Meike Ewald, Lars-Oliver Tykocinski, Hanns-Martin Lorenz and Theresa Tretter, Department of Internal Medicine V, Div. of Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Activated macrophages (Mph) can be subdivided in at least 2 major subgroups according to their polarization into classical pro-(M1-Mph) or anti-inflammatory (M2-Mph) subtypes. Together…
Abstract Number: 0121 • ACR Convergence 2023
High Prevalence of Mental Health Disorders Among Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Jeong Yee¹, Candace Feldman¹, Emily G. Oakes¹, Elizabeth Karlson¹, Jack Ellrodt¹, Laura Kubzansky², Karestan Koenen² and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are complex autoimmune diseases associated with pain and decreased quality of life. Mental health conditions related…
Abstract Number: 0266 • ACR Convergence 2023
E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez², Fernanda Genre Romero², Belén Atienza-Mateo³, Victor Mora-Cuesta⁴, David Iturbe-Fernández⁴, Leticia Lera-Gómez⁵, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Ricardo Blanco¹, Jose Cifrian⁶, Miguel A Gonzalez-Gay⁷ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the most critical comorbidities in autoimmune diseases (AD), particularly in rheumatoid arthritis (RA) and systemic sclerosis (SSc)…
Abstract Number: 0388 • ACR Convergence 2023
Left Ventricular Geometry Abnormalities Are Related to Higher Clinical Activity in Rheumatoid Arthritis Patients
Victor Beltran¹, Iris Colunga², Dionicio A. Galarza-Delgado², José Ramón Azpiri-López², Jesus Alberto Cardenas-De la Garza³, Rosa Arvizu-Rivera⁴, Valeria Gonzalez-Gonzalez⁵ and Angel Arias Peralta⁶, ¹Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) leading cause of death is cardiovascular (CV) disease. RA patients can develop silent myocardial tissue alterations, which result in changes in…
Abstract Number: 0404 • ACR Convergence 2023
Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?
Carmen Roseman, Johan Karlsson Wallman, Jon Einarsson, Elisabeth Mogard, Elisabet Lindqvist, Meliha Kapetanovic and Tor Olofsson, Lund University and Skåne University Hospital, Lund, Sweden
Background/Purpose: Persisting pain with or without inflammation control is a common and debilitating symptom in rheumatoid arthritis (RA). Concerns have been raised that patients with…
Abstract Number: 0421 • ACR Convergence 2023
Bioinformatics Platform to Study the Genetics of Biologic DMARD Non-responders: Design and Protocol of the RA Non-responders to Treatment (RANT) Study
Gregory McDermott¹, Mary Jeffway¹, Thany Seyok¹, Harrison Zhang², Kumar Dahal¹, Dana Weisenfeld¹, Margaret Vella³, Tracy Johansson⁴, Gabriela Schmajuk⁵, Kaleb Michaud⁶, Cassandra Perry³, Susanne Churchill³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴American College of Rheumatology, Atlanta, GA, ⁵UCSF / SFVA, San Francisco, CA, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although the modern RA treatment armamentarium has led to significant improvements in response rates and outcomes, some RA patients inadequately respond to multiple lines…
Abstract Number: 0438 • ACR Convergence 2023
Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review
Swetha Ann Alexander¹, Gordon Starkebaum², Diana Louden², Grant Hughes² and Namrata Singh³, ¹University of Utah Health, Salt Lake City, UT, ²University of Washington, Seattle, WA, ³University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) patients have an increased risk of developing lymphoma compared to the general population. This increased risk is believed to be linked…
Abstract Number: 0455 • ACR Convergence 2023
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
Kenneth Luu, Martin Dahl, Eric Hare, Cailin Sibley, Paul Lizzul and Bruce Randazzo, AnaptysBio, San Diego, CA
Background/Purpose: PD-1 pathway mutations increase human susceptibility to multiple autoimmune diseases, and insufficient PD-1 signaling can lead to dysregulated T cell responses. By targeting natural…
Abstract Number: 0734 • ACR Convergence 2023
Immune Isoform Atlas: Landscape of Alternative Splicing in Human Immune Cells and Involvement of Dysregulated Alternative Splicing in Autoimmune Diseases
Jun Inamo¹, Akari Suzuki², Mahoko Takahashi Ueda¹, Kensuke Yamaguchi¹, Hiroshi Nishida³, Katsuya Suzuki⁴, Yuko Kaneko⁵, Tsutomu Takeuchi⁶, Hiroaki Hatano⁷, Kazuyoshi Ishigaki⁸, Yasushi Ishihama³, Kazuhiko Yamamoto⁹ and Yuta Kochi¹, ¹Tokyo Medical and Dental University, Tokyo, Japan, ²RIKEN Center for Integrative Medical Science, Kanagawa, Japan, ³Kyoto University, Kyoto, Japan, ⁴Keio University, Shinjuku, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁷Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ⁸RIKEN, Tokyo, Japan, ⁹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: Alternative splicing events play a critical role in the immune system1,2 and one of major causal mechanisms for complex traits including immune-mediated diseases (IMDs),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].